A Rich History
Toronto has a rich history in pharmacogenetics. In the 1950s, University of Toronto Professor Werner Kalow was a pioneer in establishing pharmacogenetics, a new discipline at that time, based at the intersection of pharmacology and genetics. CAMH became a leader in psychiatric pharmacogenetics, opening one of the world’s first Pharmacogenetics Research Clinics for mental illness in 2008.
The Tanenbaum Centre for Pharmacogenetics was established in 2012, with the philanthropic support of Larry and Judy Tanenbaum. As part of the flagship IMPACT study that followed, more than 10,000 patients referred by over 3,000 clinicians across Ontario have completed pharmacogenetics testing through CAMH.
Identifying new genetic and epigenetic variants involved in treatment response and side-effects to antipsychotics, antidepressants and mood stabilizers
Design new, improved diagnostic psychiatric pharmacogenetic variant testing panels for patients who have been prescribed, or will be prescribed, antipsychotic and/or antidepressant medication
Determining the frequencies of known pharmacogenetic variants in two Ontario First Nations populations in collaboration with CAMH’s Institute for Mental Health Policy Research
Development of a computerized search of electronic medical records, along with artificial intelligence processing, to rapidly track the response and development of side-effects in our study participants.